Isabel Cameron

Dec 10, 2024 | outsourcing-pharma.com | Larissa Warneck-Silvestrin |Liza Laws |Isabel Cameron |Almac Group

Pharma company, AbbVie, reports that its D1/D5 partial agonist, tavapadon, has met the primary and secondary endpoints in a pivotal Phase 3 trial. The trial, called TEMPO-2, evaluated the investigational drug as a flexible-dose monotherapy for individuals with early Parkinson’s disease. Tavapadon is the first partial agonist of the dopamine receptors D1/D5, helping to activate them in people with Parkinson’s disease. About suffer from Parkinson’s disease, with the number expected to double by 2050.

Oct 24, 2024 | biopharma-reporter.com | Helen Albert |Liza Laws |Isabel Cameron

Alto Neuroscience has a focus on developing new neuropsychiatric medications. The company is using a combination of artificial intelligence (AI), brain activity and biomarker analysis to select new and better targeted potential drug candidates to advance to clinical trials. ALTO-100 was originally developed by Neuralstem, which became Palisade Bio. It is an oral, small molecule drug that is designed to treat people with low levels of brain-derived neurotrophic factor (BDNF).

Aug 2, 2024 | newsweek.com | Isabel Cameron

Seattle has been crowned the smartest city in the United States, but what factors determined this?

Jul 31, 2024 | newsweek.com | Isabel Cameron

Gen X and millennials face rising cancer risks compared to boomers regarding several types of the illness, according to the American Cancer Society.

Jul 10, 2023 | biopharma-reporter.com | Isabel Cameron